Inozyme Pharma, Inc. Common Stock

INZY XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

American Express® Business Gold Card

Earn Up to 200K Membership Rewards® Points

4X on your top 2 spending categories. Transfer to 20+ airline & hotel partners. Terms apply.

Learn More

Market Cap

260M

Short interest (May 30)

5.7%

Net Short (Jun 30 ): 0.1%

Borrow Fee

1.60%

Available Shares

Price Chart

Company Overview

Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001693011

Asset Type: CS

Market Data

Market Cap: $257,601,677

Employees: 67

Status: Active

Short Interest

Current Borrow Fee 1.60%

Range: 1.60% - 1.60%

Available Shares 0

Range: 0 - 0

Recent Changes

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime